Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Thrombin
    (2)
  • Endogenous Metabolite
    (1)
  • Factor Xa
    (1)
  • Interleukin
    (1)
  • P2Y Receptor
    (1)
  • Prostaglandin Receptor
    (1)
  • RSV
    (1)
  • SARS-CoV
    (1)
  • Others
    (4)
TargetMol | Tags By ResearchField
  • Cardiovascular System
    (3)
  • Infection
    (1)
  • Inflammation
    (1)
  • Metabolism
    (1)
  • Nervous System
    (1)
  • Others
    (1)
Filter
Search Result
Results for "

percutaneous

" in TargetMol Product Catalog.
  • Inhibitors & Agonists
    8
    TargetMol | All_Pathways
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Natural Products
    1
    TargetMol | Natural_Products
  • Bivalirudin
    Hirulog-1, BG-8967
    T5519128270-60-0
    Bivalirudin (BG-8967) is a reversible inhibitor of α- and ζ-thrombin (Kis = 2.56 and 1.84 nM, respectively), enzymes that exhibit high fibrinogen-clotting activities.
    • $29
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Prasugrel
    PCR 4099, LY640315, CS-747
    T0230150322-43-3
    Prasugrel (CS-747) is a piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.
    • $37
    In Stock
    Size
    QTY
  • Laurocapram
    Tranzone, N-Lauryl caprolactam, N-Dodecylcaprolactam, N-0252, Azone
    T2A250959227-89-3
    Laurocapram (N-Lauryl caprolactam) is a percutaneous enhancer. Upon application to the skin, laurocapram interacts with lipids in the stratum corneum and may enhance the ability of the skin to absorb a hydrophilic chemical.
    • $29
    In Stock
    Size
    QTY
  • trans-Cyclohexane-1,2-diol
    trans-1,2-Cyclohexanediol
    T47631460-57-7
    trans-Cyclohexane-1,2-diol (trans-1,2-Cyclohexanediol) has a synergistic retardation effect on percutaneous absorption and penetration of metronidazole (MTZ).
    • $29
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Enoxaparin sodium
    T22323679809-58-6
    Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI)
    • $31
    In Stock
    Size
    QTY
  • C16 Phytoceramide (t18:0/16:0)
    T38180111149-09-8
    C16 Phytoceramide (t18:0/16:0) is a phytoceramide, which is a family of sphingolipids found in the intestine, kidney, and extracellular spaces of the stratum corneum of the mammalian epidermis. C16 Phytoceramide (t18:0/16:0) is composed of a phytosphingosine backbone amine-linked to a C16 fatty acid chain. The levels of C16 phytoceramide (t18:0/16:0) increase following heat stress in S. cerevisiae. It has been used with other ceramides to create stratum corneum substitutes to study percutaneous penetration and psoriasis in vitro.
    • $276
    Inquiry
    Size
    QTY
  • C24 Phytosphingosine (t18:0/24:0)
    T3829134437-74-6
    C24 Phytosphingosine (t18:0/24:0) is a phytoceramide, which is a family of sphingolipids found in the intestine, kidney, and extracellular spaces of the stratum corneum of the mammalian epidermis. C24 Phytosphingosine (t18:0/24:0) is composed of a phytosphingosine backbone amine-linked to a C24 fatty acid chain. It has been used with other ceramides to create stratum corneum substitutes to study percutaneous penetration and psoriasis in vitro. In a stratum corneum model of healthy skin, the incorporation of long-chain-containing phytoceramides, such as C24 phytosphingosine (t18:0/24:0), increases permeability of the membrane in comparison with incorporation of dihydroceramides.
    • $185
    35 days
    Size
    QTY
  • Ciprostene (free base)
    T6863981845-44-5
    Ciprostene (free base) is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-induced platelet aggregation. Ciprostene was evaluated in clinical trials in patients with peripheral vascular disease. It was found to reduce restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty.
    • $2,120
    8-10 weeks
    Size
    QTY